A company called Viking Therapeutics is working on making new medicines. Some people who watch the stock market think this company's value will go up or down. They use something called options to bet on that. An analyst from Stifel thinks it will be worth $80, while another one from Oppenheimer says $116. Two other analysts also like Viking Therapeutics and think it could be worth more than $90. This article is about what these people are saying and how they use options to make their predictions. Read from source...

1. The title of the article is misleading and sensationalized. It does not reflect the actual content or tone of the text. A more accurate title would be "Viking Therapeutics Options Activity: Analysts' Ratings and Price Targets". This title would better capture the main focus of the article, which is to report on different analysts' opinions and recommendations for Viking Theraptics.
2. The article introduces a price target of $90 without providing any context or justification for this figure. Where did this number come from? What are the assumptions and methodology behind it? A more transparent and informative introduction would be needed to explain the rationale behind the $90 price target.
3. The article uses vague and subjective terms such as "unusual" and "cautious" to describe the options activity for Viking Therapeutics. These words do not convey any meaningful or actionable information to the reader. They only serve to create a sense of curiosity and intrigue, without delivering any substance or insight. A more objective and analytical approach would be needed to assess the options activity and explain its implications for the stock.
4. The article does not provide any historical context or comparison for the analysts' ratings and price targets. How have these ratings and price targets changed over time? How do they compare to other similar companies in the same sector or industry? What are the factors that influence these changes and fluctuations? A more comprehensive and comparative analysis would be needed to provide a deeper understanding of the options activity for Viking Therapeutics.
5. The article ends with a promotional message for Benzinga Pro, which is irrelevant and inappropriate for the content of the article. This message detracts from the credibility and professionalism of the article and attempts to manipulate the reader into signing up for a paid service. A more ethical and respectful conclusion would be needed to wrap up the article without resorting to sales tactics or pressure.

1. Based on the article, Viking Therapeutics has shown unusual options activity with a new price target of $90. This suggests that there is significant interest from institutional investors who are bullish on the stock's potential to rise further. However, this also implies higher volatility and uncertainty in the market, which could lead to sharp swings in both directions. Therefore, if you are considering investing in Viking Therapeutics, you should be prepared for the possibility of losses as well as gains.